Abstract
Neratinib is an efficacious HER2-targeted agent for HER2+ ESBC, although its potential clinical benefits among the incident U.S. HR+ HER2+ high-risk ESBC patient population following use of T-DM1 or pertuzumab have not been quantified. Our objective was to estimate the long-term potential treatment benefits of neratinib in this target population.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call